Watchlist Price Alert

Corcept Therapeutics (CORT)

NASDAQ: CORT · Real-Time Price · USD

74.12

1.35 (1.86%)

At close: May 05, 2025, 3:59 PM

69.40

-6.37%

After-hours: May 05, 2025, 07:56 PM EDT

1.86% (1D)

Bid	68.58
Market Cap	7.82B
Revenue (ttm)	675.04M
Net Income (ttm)	140.69M
EPS (ttm)	1.23
PE Ratio (ttm)	60.26
Forward PE	20.26
Analyst	Strong Buy

Ask	75
Volume	1,457,473
Avg. Volume (20D)	1,604,440
Open	72.01
Previous Close	72.77
Day's Range	71.34 - 74.30
52-Week Range	23.02 - 117.33
Beta	0.14

About CORT

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 14, 2004

Employees 500

Stock Exchange NASDAQ

Ticker Symbol CORT

Website https://www.corcept.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for CORT stock is "Strong Buy." The 12-month stock price forecast is $146, which is an increase of 96.98% from the latest price.

Stock Forecasts

Earnings Surprise

New

Corcept Therapeutics has released their quartely earnings on May 5, 2025:

Revenue of $157.21M misses estimates by $20.72M, with 7.09% YoY growth.

EPS of 0.17 exceeds estimates by 0.03, with -32.00% YoY decline.

Next Earnings Release

Corcept Therapeutics is scheduled to release its earnings on May 5, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Just now New

+1.61%

Corcept Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

1 month ago

+109.08%

Corcept Therapeutics shares are trading higher after the company announced it met its primary endpoint for its Phase 3 ROSELLA trial of Relacorilant.

News

18 hours ago · seekingalpha.com

Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrino...

20 hours ago · zacks.com

Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.25 per share a year ago.

1 week ago · businesswire.com

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. Th...

1 week ago · businesswire.com

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...

1 week ago · seekingalpha.com

Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss

Despite a Q4 revenue miss, Corcept's 2025 revenue still grew 40% to $675 million, and management provided strong guidance for 2025 and beyond, projecting up to $5 billion in revenue. Corcept's potenti...

2 weeks ago · businesswire.com

Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

2 weeks ago · seekingalpha.com

It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder

Corcept is transitioning from a single-product company to a multi-product, multi-market Platform Growth™ company, promising rapid revenue and earnings growth. Relacorilant's success in platinum-resist...

3 weeks ago · marketbeat.com

3 Biopharmaceutical Stocks Bucking the Sell-Off

With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be look...

4 weeks ago · businesswire.com

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

1 month ago · zacks.com

Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positi...

Load More News